Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma

Scott, Jeffrey R.; Ward, Deborah; Crews, Kristine R.; Panetta, John C.; Navid, Fariba

doi:10.1002/pbc.24741

Cited by 12 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared with the case reported , our patient suffered more severe cardiovascular impairment and liver toxicity. Our experience supports the conclusion that it is not necessary to exclude methotrexate from the treatment plan after an even severe hypersensitivity reaction.…”

contrasting

confidence: 78%

“…To the Editor: We read with great interest the report describing a case of successful readministration of high‐dose methotrexate (HD MTX) after a hypersensitivity reaction. We would like to support the conclusions with our own recent experience.…”

mentioning

confidence: 99%

“…

…”

mentioning

confidence: 99%

See 2 more Smart Citations

Can high dose methotrexate be continued after severe hypersensitivity reaction?

Antonio¹,

Bisogno²

2013

Pediatric Blood & Cancer

View full text Add to dashboard Cite

We read with great interest the report [1] describing a case of successful readministration of high-dose methotrexate (HD MTX) after a hypersensitivity reaction. We would like to support the conclusions with our own recent experience.A 16-year-old female was diagnosed with a localized osteoblastic osteosarcoma of the right humerus. She had no associated comorbidities and began treatment according to the Italian Sarcoma Group OS-2 (ISG/OS-2) protocol. She received a first course of HD MTX (12 g/m 2 in 4 hours) with normal drug clearance and good tolerance. The second course was complicated by moderately elevated transaminases and emesis. The patient underwent surgery and good histological response to neoadjuvant chemotherapy was documented.Fifteen minutes after completing the infusion of the third course of HD MTX the patient developed abdominal pain, emesis, emission of loose stools, and persistent hypotension. She received fluid resuscitation, two doses of hydrocortisone and two doses of im. adrenaline. After 1 hour, her blood pressure normalized and her clinical symptoms faded. Four hours after completing the infusion, the concentration of MTX in blood was 350 mmol/L; at the same time blood tests revealed altered coagulation and elevated liver enzymes (AST 2,905 U/L, ALT 2,594 U/L). Due to signs of rapid and severe organ damage, the patient was given high-dose calcium levofolinate and glucarpidase; 1 hour after such treatment her MTX level was 9.95 mmol/L and reached 0.43 mmol/L 32 hours later.Given the importance of HD MTX in the treatment of osteosarcoma, we decided to continue with its administration. The next course was given after premedication with methylprednisolone and chlorphenamine, and the timing of MTX infusion was extended to 6 hours, starting with 400 mg of MTX/m 2 /h and gradually increasing the infusion rate. The total dose was unchanged (12 g/m 2 ). The patient reported no symptoms or signs during or after the next two MTX infusions, apart from a moderate elevation in liver enzymes. The MTX levels measured in the blood 24 and 48 hours after starting the infusion did not differ substantially from those measured after the first two cycles.Compared with the case reported [1], our patient suffered more severe cardiovascular impairment and liver toxicity. Our experience supports the conclusion that it is not necessary to exclude methotrexate from the treatment plan after an even severe hypersensitivity reaction. This may be a crucial issue for osteosarcoma patients because methotrexate is essential to their treatment. Giving adequate premedication, prolonging the infusion time from 4 to 6 hours and increasing the infusion rate gradually seem to allow safe re-administration of HD MTX.

show abstract

contrasting

confidence: 78%

mentioning

confidence: 99%

See 1 more Smart Citation

Can high dose methotrexate be continued after severe hypersensitivity reaction?

Antonio¹,

Bisogno²

2013

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…As reações de hipersensibilidade ao metotrexato são raras mas estão descritas. 21,22 Independentemente da dose usada, associa-se a reações de hipersensibilidade que variam desde reações ligeiras a reações quase fatais. 2 As reações surgem habitualmente após várias administrações, embora estejam descritas reações graves com a administração da primeira dose de metotrexato.…”

Section: Metotrexatounclassified

Reações de Hipersensibilidade a Citostáticos em Idade Pediátrica

Castro

Morais‐Almeida

2018

Gaz Med

View full text Add to dashboard Cite

As reações de hipersensibilidade a antineoplásicos podem variar entre reações ligeiras a reações anafiláticas fatais e podem ser desencadeadas virtualmente por qualquer citostático. Na ausência de uma alternativa viável, a dessen-sibilização pode ser a única forma de prosseguir a terapêutica. Pretendeu-se com este artigo rever a literatura inde-xada publicada sobre este tema, de modo a caracterizar as reações de hipersensibilidade associadas aos fármacos citostáticos mais frequentemente utilizados em idade pediátrica e a sua abordagem.

show abstract

“…89,90 Methotrexate-induced pneumonitis (MIP) is an idiosyncratic hypersensitivity reaction that is significantly more common, with some case series reporting prevalence as high as 12%, although this is chiefly in the rheumatoid arthritis literature. 87,91,92 The prevalence of methotrexate hypersensitivity pneumonitis in patients with CD is more likely between 0.3 and 0.7%, 92 although a recent meta-analysis found that MTX use in rheumatologic and inflammatory bowel disease was not associated with an increased risk of adverse respiratory events (RR, 1.03; 95% CI, 0.9–1.17).…”

Section: Immunomodulatorsmentioning

confidence: 99%

Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease

Cohn

Dave

Loftus

2017

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Ulcerative colitis and Crohn’s disease are chronic inflammatory bowel diseases for which there are no cures. These diseases are immunopathogenic, and medical treatment is centered on the temperance of a dysregulated immune response to allow mucosal healing and prevent the sequelae of fistulation and stenosis. Accordingly, the armamentarium of medications, which has expanded immensely in recent history, is not without significant infectious and neoplastic risks. Many of these untoward effects can be mitigated by screening and avoidance of contraindicated medications. This review seeks to highlight the cautions for use of immunomodulators, anticytokine and α4-integrin antagonists. The potential adverse events are further complicated by substantial heterogeneity in disease phenotype in the IBD population. Large patient registries and databases provide considerable experience and knowledge to calculate the incidence of safety outcomes. To identify rarer outcomes after prolonged therapy, more prospective studies and continued adverse event reporting will aid safe application and minimize potential harms.

show abstract

Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma

Cited by 12 publications

References 17 publications

Can high dose methotrexate be continued after severe hypersensitivity reaction?

Can high dose methotrexate be continued after severe hypersensitivity reaction?

Reações de Hipersensibilidade a Citostáticos em Idade Pediátrica

Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease

Contact Info

Product

Resources

About